HSF2 reduced the decrease in the MMP in Caco-2 cells, which were observed by laser confocal microscopy. حسب Wen Wang (6570)

"…Red fluorescence indicated that there was no obvious abnormality in the MMP, while green fluorescence represented a decrease in the MMP. B: Statistical bar chart of the ratio of red to green fluorescence, <i>P</i> value of less than 0.05 was identified as* and <i>P</i> value of less than 0.01 was identified as**. …"

<i>Toxoplasma gondii</i> chronic infection decreases visceral nociceptive responses in the absence of macroscopic colonic inflammation. حسب Alexis Audibert (21213531)

Decreased visceral nociceptive responses induced by <i>Toxoplasma gondii</i> chronic infection relies on peripheral opioid signaling. حسب Alexis Audibert (21213531)

A summary of the included study characteristics. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

Response distributions for the questions that represent the latent variable ‘cautious sexual attitudes’. حسب Abigail A. Lee (19935335)

Fit statistics for CFA analysis of the latent variable “intent to vaccinate against HPV”. حسب Abigail A. Lee (19935335)

Posterior distribution of the effect of the latent variable on the probability of seeking traditional remedies after a potential dog bite indicates a decreased likelihood of individuals seeking traditional remedies. حسب Philip P. Mshelbwala (11278898)

"…<p>Posterior distribution of the effect of the latent variable on the probability of seeking traditional remedies after a potential dog bite indicates a decreased likelihood of individuals seeking traditional remedies.…"

List of Included studies. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

The search strategy in three databases. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

NIH score. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

List of excluded studies. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

Symbols and meanings. حسب Yan Wen (416285)

Naringenin decreases mitochondrial function. حسب Lauren A. Eanes (20995499)

Average days (mean) to heal a wound in 2022 and 2023. حسب Heba Tallah Mohammed (2822432)

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

Study 2_Experiment 2. حسب Chen-Yueh Chen (9740047)

"…In Study I, a five-phase framework for developing a measurement scale is adopted including items generation, items refinement and edition, exploration of the latent factor structure of the scale and confirmation of reliability, examination of the structure of the factors, and scale validation. …"

Study 2_Experiment 3. حسب Chen-Yueh Chen (9740047)

"…In Study I, a five-phase framework for developing a measurement scale is adopted including items generation, items refinement and edition, exploration of the latent factor structure of the scale and confirmation of reliability, examination of the structure of the factors, and scale validation. …"

Study 1_EFA. حسب Chen-Yueh Chen (9740047)

"…In Study I, a five-phase framework for developing a measurement scale is adopted including items generation, items refinement and edition, exploration of the latent factor structure of the scale and confirmation of reliability, examination of the structure of the factors, and scale validation. …"

Study 2_Experiment 4. حسب Chen-Yueh Chen (9740047)

"…In Study I, a five-phase framework for developing a measurement scale is adopted including items generation, items refinement and edition, exploration of the latent factor structure of the scale and confirmation of reliability, examination of the structure of the factors, and scale validation. …"

Study 1_CFA1. حسب Chen-Yueh Chen (9740047)

"…In Study I, a five-phase framework for developing a measurement scale is adopted including items generation, items refinement and edition, exploration of the latent factor structure of the scale and confirmation of reliability, examination of the structure of the factors, and scale validation. …"